I think you're right, Iceman. Something does have to give on this one and I think spinning off the Vax division would actually see results in the SP over the next 6 months. It would, at the least, show just how much in real terms the division has been costing the company and I'd wager blast us across truly CF+ in short order.
It's not about the SP right now though, it's about decisive action. Either prove the Vax division has legs in terms of a real HPV collab with $$, or divest it.
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-184
-
- There are more pages in this discussion • 167 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.60 |
Change
-0.100(0.53%) |
Mkt cap ! $357.5M | |||
| Open | High | Low | Value | Volume |
| $18.70 | $18.77 | $18.21 | $664.1K | 35.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $18.50 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.69 | 53 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |